TIL · Insider Trading
Instil Bio, Inc. Common Stock
Every open-market purchase and sale reported by TIL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | R Kent McGaughy Jr | Director | A | +6,500 deriv. | — |
| 2026-06-12 | Neil W Gibson | Director | A | — | — |
| 2026-06-12 | Gwendolyn Binder | Director | A | +6,500 deriv. | — |
| 2026-06-12 | George Matcham | Director | A | +6,500 deriv. | — |
| 2025-09-12 | Sandeep Laumas | CFO and CBO | MIXED | — | −$339.63K |
| 2025-05-29 | R Kent McGaughy Jr | Director | A | +6,500 deriv. | — |
| 2025-05-29 | George Matcham | Director | A | +6,500 deriv. | — |
| 2025-05-29 | Gwendolyn Binder | Director | A | +6,500 deriv. | — |
| 2025-05-29 | Neil W Gibson | Director | A | +6,500 deriv. | — |
| 2025-04-28 | Sandeep Laumas | CFO and CBO | A | +44,851 deriv. | — |
| 2025-04-28 | Bronson Crouch | CEO and Chairman | A | +105,157 deriv. | — |
| 2024-09-23 | Bronson Crouch | CEO and Chairman | A | +50,000 deriv. | — |
| 2024-09-23 | Sandeep Laumas | CFO and CBO | A | +45,000 deriv. | — |
| 2024-06-13 | Gwendolyn Binder | Director | A | +5,000 deriv. | — |
| 2024-06-13 | R Kent McGaughy Jr | Director | A | +5,000 deriv. | — |
| 2024-06-13 | George Matcham | Director | A | +5,000 deriv. | — |
| 2024-06-13 | Neil W Gibson | Director | A | +5,000 deriv. | — |
| 2024-02-13 | Sandeep Laumas | CFO and CBO | A | +80,000 deriv. | — |
| 2024-02-13 | Bronson Crouch | CEO and Chairman | A | +120,000 deriv. | — |
| 2024-01-10 | George Matcham | Director | A | +1,500 deriv. | — |
| 2024-01-10 | Neil W Gibson | Director | A | +1,500 deriv. | — |
| 2024-01-10 | R Kent McGaughy Jr | Director | A | +1,500 deriv. | — |
| 2024-01-10 | Gwendolyn Binder | Director | A | +1,500 deriv. | — |
| 2024-01-10 | Jack Nielsen | Director | A | +1,500 deriv. | — |
| 2023-01-20 | Sandeep Laumas | CFO and CBO | A | +234,000 deriv. | — |
| 2023-01-20 | Bronson Crouch | CEO and Chairman | A | +1,000,000 deriv. | — |
| 2023-01-20 | Bronson Crouch | CEO and Chairman | A | +750,000 deriv. | — |
| 2023-01-20 | Sumita Ray | Chief Legal and Admin Officer | A | +465,000 deriv. | — |
| 2023-01-20 | Sandeep Laumas | CFO and CBO | A | +415,000 deriv. | — |
| 2022-09-06 | Timothy L. Moore | Chief Operating Officer | A | +750,000 deriv. | — |
| 2022-05-25 | Jack Nielsen | Director | A | +30,000 deriv. | — |
| 2022-05-25 | George Matcham | Director | A | +30,000 deriv. | — |
| 2022-05-25 | R Kent McGaughy Jr | Director | A | +30,000 deriv. | — |
| 2022-05-25 | Vijay Chiruvolu | Chief Technical Officer | A | +154,237 deriv. | — |
| 2022-05-25 | Neil W Gibson | Director | A | +30,000 deriv. | — |
| 2022-05-25 | Gwendolyn Binder | Director | A | +30,000 deriv. | — |
| 2022-03-17 | R Kent McGaughy Jr | Director | J | −260,323 | — |
| 2022-03-07 | Sandeep Laumas | CFO and CBO | A | +234,000 deriv. | — |
| 2022-03-07 | Vijay Chiruvolu | Chief Technical Officer | A | +257,000 deriv. | — |
| 2022-03-07 | Bronson Crouch | CEO and Chairman | A | +750,000 deriv. | — |
| 2022-03-07 | Zachary Roberts | Chief Medical Officer | A | +245,000 deriv. | — |
| 2021-10-08 | Zachary Roberts | Chief Medical Officer | A | +120,000 deriv. | — |
| 2021-09-13 | Zachary Roberts | Chief Medical Officer | A | +120,000 deriv. | — |
| 2021-05-13 | Bronson Crouch | CEO and Chairman | A | +750,000 deriv. | — |
| 2021-05-13 | Zachary Roberts | Chief Medical Officer | A | +200,000 deriv. | — |
| 2021-05-13 | Sandeep Laumas | CFO and CBO | A | +200,000 deriv. | — |
| 2021-05-13 | Vijay Chiruvolu | Chief Technical Officer | A | +354,237 deriv. | — |
| 2021-03-25 | R Kent McGaughy Jr | Director | MIXED | +8,478,790 | +$9.00M |
| 2021-03-25 | Jack Nielsen | Director | MIXED | +12,486,787 | +$6.00M |
| 2021-03-25 | Vivo Capital Fund IX, L.P. | 10%+ Owner | MIXED | +24,973,574 | +$12.00M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bronson Crouch | CEO and Chairman | 2,025,898 | $11.28M |
| R Kent McGaughy Jr | Director | 410,923 | $2.29M |
| Sandeep Laumas | CFO and CBO | 12,461 | $69.41K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TIL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.